Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
Date:8/1/2011

f Arena's most advanced drug candidate and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looki
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
2. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
3. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
4. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
7. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
9. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
10. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... focus on Omega-3 therapies for cardiovascular disease and overall ... 763,752 common shares of the Corporation (the "Common Shares"). ... period of December 5 th , 2014 to March ... that is due on or before April 1, 2015. ...
(Date:3/26/2015)... 26, 2015 "Whether it,s our family, our ... In a single sentence, Dr. Anthony ... at Pfizer,s Centers for Therapeutic Innovation (CTI), ... progress at America,s biopharmaceutical companies. CTI,s ... academia, patient foundations and the National Institutes of Health ...
(Date:3/26/2015)... Mich. , March 26, 2015 Cardiologists ... have performed the Midwest,s first commercial implant of a ... for patients with non-valvular atrial fibrillation. The Watchman Left ... use of blood-thinning warfarin medication to reduce the risk ... common heart rhythm disorder affecting more than 5 million ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
(Date:3/27/2015)... 2015 Ticket Down is a reputable source for ... After a phenomenal and highly successful live tour last year, ... out on tour again in 2015 and they will be visiting ... April 29th in New York City at the cozy Beacon Theatre ... on May 10th. , Fans of the hit show can look ...
(Date:3/27/2015)... BC (PRWEB) March 27, 2015 According ... ( http://www.idataresearch.com ), the plate and screw market in ... in the generic plate and screw segment. Price decreases ... market. Despite representing almost 50% of the total European ... to decrease the total market value, year after year. ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 GrassrootsHealth, ... its Protect Our Children (POC) NOW! vitamin D demonstration ... Medical University of South Carolina (MUSC), and will soon ... be available at no cost to a minimum of ... who live within these two service areas. The project ...
Breaking Medicine News(10 mins):Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4
... categories for// printed letters and sounds, says a new study. ... filter out visual disturbances that may obscure the pattern of ... scientists from University of Southern California, US, brings out a ... dyslexic brain. ,Dyslexia is a learning disorder in ...
... lose knee lubrication following an injury to the knee. This ... of Rhode Island had identified a way to find out ... after a knee injury, in order to find out whether ... ,Although knee injury is considered to be a risk factor ...
... based study had found that children are more exposed ... anywhere else. ,Allergens that are commonly found indoor ... dust and dust mites, cockroaches and pollens. These may ... and various other diseases. Some of the symptoms experienced ...
... People who have survived cancer may have higher risks ... ,Researchers from University of Southern California had found ... long life have twice as much risk as their ... have studied 702 survivors of cancer and their twins ...
... in conceiving and// delivering world’s first baby born from ... the baby had her eggs collected from her, frozen ... fertilized from sperms of her partner through in-vitro fertilization ... in her uterus, which she carried to a full ...
... to air pollutions of big// cities may harm their ... of polluted air of the metros can change the ... from the cars, trucks, buses, tobacco smoke, combustion etc ... of the fetus. , ,The research conducted by ...
Cached Medicine News:
... All of DOA Panel Test ... step in vitro test. It ... drug substances in human urine ... evaluated in the point of ...
... is an immunochromatography based one step ... qualitative determination of amphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... fully automated, user-friendly system that helps ... and improve patient care. This state-of-the-art ... testing capabilities with a complete menu ... also a powerful, intuitive system that ...
... in-vitro diagnostic test kit for the ... in human serum/plasma. This test is ... gelatin particles coated with inactivated Trypanosoma ... are agglutinated in the presence of ...
Medicine Products: